Table 4.

Group A: patients treated with local therapy or systemic therapy ‘less than CHOP’

Pat.	Age/sex	Cutaneous manifestations	Extracutaneous manifestations	Initial therapy	CR/PR	Survival (months)
2	63/m	+	+	COP	No	61/2
3	47/f	+	−	RT, PUVA, IFN-α	No	17+ (AWD)
4	81/f	+	+	Prednisone	PR	10
5	82/m	+	+	COP+mitoxantrone	CR	8
6	79/m	+	+	Prednisone	CR	3
8	72/m	+	+	RT	No	5
12	89/m	+	−	IL-2, RT	CR	20
15	21/f	+	−	RT	CR	18+
16	86/f	+	+	COP	CR	5
18	67/f	+	−	COP-C	CR	17
19	84/m	+	+	CP	CR	5
20	65/f	+	+	COP-C	CR	17
25	83/m	+	+	COP	No	19
26	89/f	+	+	RT	PR	5
27	82/m	+	+	Etoposide + prednisone +IFNα/γ	CR	8
36	67/f	+	−	COP-C	CR	16
49	76/m	−	+	Symptomatic	No	3
51	81/f	+	+	COP	CR	12
53	69/m	+	+	COP	CR	12
58	79/m	+	−	Cyclophosphamide, etoposide, Prednisone	CR	8
67	67/m	+	+	6-Mercaptopurine, MTX, prednisone	PR	12+
68	70/m	+	+	COP	CR	7
70	79/m	+	+	Vincristine, prednisone	CR	6
77	86/m	+	−	RT	CR	ND
87	64/m	+	+	CEP	CR	6+ (PD)
88	88/f	+	−	HU	No	8
89	72/m	+	+	Cyclophosphamide, MTX, vincristine + i.th.	CR	14+
90	81/m	+	−	RT	CR	22+ (AWD)
n=28	Med. 79	27/28 96%	19/28 68%		19CR 68%	Med. OS 9
	m:f 18:10				3PR 11%	CR at last follow-up 2/28 (7%)

AWD: alive with disease; CEP: cyclophosphamide, eldisine, prednisolone; COP: cyclophosphamide, vincristine, prednisone; COP-C: COP+ chlorambucil; HU: hydroxyurea; IFN-α: interferon-alpha; IFN-γ: interferon-gamma; IL-2: interleukin-2; i.th: intrathecal; MTX: methotrexate; PUVA: psoralen plus ultraviolet A therapy; RT: radiotherapy; CR: complete remission; PR: partial remission; ND: not determined.